Overview
- First-half revenue fell 4% to $8.33 billion, with underlying net profit at $1.92 billion versus $2.11 billion a year earlier on a constant currency basis.
- CSL Behring revenue declined 7%, including a 6% drop in immunoglobulin sales and a 27% fall in albumin.
- The board expanded the share buyback by $250 million to $750 million, and the interim dividend was held at $1.30 per share.
- CSL expects roughly $1.1 billion in after-tax, non-restructuring impairments for the full year, says most are already recognised, and reports delivery of about 60% of targeted FY26 cost savings.
- Full-year guidance was maintained for modest revenue growth and a 4%–7% rise in underlying profit, while Seqirus posted $1.6 billion in revenue, down 2%, ahead of a planned spinoff.